The changing role of ER in endocrine resistance
Agostina Nardone(AstraZeneca (Spain)), Rachel Schiff(Baylor College of Medicine), Carmine De Angelis(Baylor College of Medicine), C. Kent Osborne(Baylor College of Medicine), Meghana V. Trivedi(University of Houston)
Cited by 133
Related Papers
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
|Cancer Research|2008|494
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485